qepler

- 12+ Program Hours
- Networking
- Panel Discussions | Q & A
- Video Recording

SPONSORS

intertek
Total Quality. Assured.

3P innovation

2nd Annual

INHALED DRUG DELIVERY SUMMIT 2021

5-6 August 2021

● VIRTUAL CONFERENCE

hopin

12:00 - 19:00 CEST (Prague - UTC/GMT +2 hours)

AGENDA WEB LinkedIn HOPIN

qepler

SPEAKERS BOARD

Dr. Andrew Feilden, CSci CChem FRSC
European E&L strategic Director
Hall Analytical, UK

Dr. John N Pritchard
Independent Business Owner
Inspiring Strategies, UK

Dr. Herbert Watchel
Senior Principal Scientist
Boehringer Ingelheim
Pharma GmbH & Co. KG, DE

Dr. Felix Weiland
Head of Product & Process Technology
Boehringer Ingelheim microParts
GmbH, DE

Thomas Sécher
Scientist
INSERM, FR

Dr. Carsten Ehrhardt
Professor in Pharmaceutics and
Biopharmaceutics
Trinity College
Dublin, IE

Nina Hobi
CEO & Scientific Director
AlveoliX AG, CH

Univ.-Prof. **Dr. Sven Stegemann**
Professor for Patient Centric Drug
Development & Manufacturing
Graz University of Technology,
AT

Mark Parry
Technical Director
Intertek Pharmaceutical Services, UK

Tom French
Device Industrialisation Engineer
3P innovation, UK

Dr. Orest Lastow, PhD
Chief Technology Officer & Founder
Iconovo AB, SE

Dr. Simon Moore, BSc(Hons) PhD MRSC
Global Lead of Inhalation Sciences and
Engineering
Covance Laboratories, UK

James B Fink, PhD, RRT, FAARC, FCCP
Chief Scientific Officer
Aerogen Pharma Corp., USA

Khaudeja Bano, MD
Executive Medical Director
Head of Combination and
Device Product Safety
Amgen, USA

YOUR 'GO-TO' DPI AUTOMATION EXPERTS

DEVICE ASSEMBLY: PLUS A RANGE OF POWDER DISPENSERS FOR RESERVOIR, BLISTER OR CAPSULE BASED DEVICES.

R500/R1000
Robotic powder dispensing for devices and capsules

CUSTOM CONTAINERS

Micro-auger



Fill2Weight - our award-winning technology for gravimetric powder dispensing

POWDER FILLING

Our versatile range of powder filling solutions will enable you to fill inhalers, capsules, and custom medical devices on one technology.

At 3P, our powder filling range has been designed with pharmaceutical and biotechnology applications in mind.

DEVICE AUTOMATION

Whether you need filling, heat sealing, welding, or component assembly our platform technologies are available to take you from clinical to commercial scale.

CONTACT US

+44 (0) 1926 408 933

enquiries@3pinnovation.com

www.3pinnovation.com

WHO YOU WILL MEET

qepler

intertek
Total Quality. Assured.

Tel: +41 61 686 4800
Fax: +44 61 686 4899
Email: business.support@intertek.com
Website: www.intertek.ch

Intertek is the industry leader with over 42,000 people in 1,000 locations in over 100 countries. Whether your business is local or global, we can ensure your products meet quality, health, environmental, safety, and social accountability standards for virtually any market around the world. We hold extensive global accreditations, recognitions, and agreements, and our knowledge of and expertise in overcoming regulatory, market, and supply chain hurdles is unrivaled.

Intertek (Schweiz) AG provides a comprehensive range of Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) compliant analytical services including chemical trace analysis, reverse engineering, complex analyses, substance identification, method development, and a wide range of other applications in conjunction with consulting expertise and engineering support.

Intertek - WEBINARS:

- Webinar Recording: Repurposing Products for Inhaled Delivery - Rapid Response Strategies
  https://www.intertek.com/knowledge-education/webinars/rapid-repurposing-for-inhaled-delivery/
- Webinar: Formulation and Manufacturing Approaches for Nasal Drug Products
  https://www.intertek.com/knowledge-education/webinars/webinar-formulation-nasal-drug-products/
- Article: In Vitro Bioequivalence for Pulmonary and Nasal Delivery
  https://www.intertek.com/knowledge-education/invitro-bioequivalence-generic-oindp-article/

SNAPSHOT OF ATTENDEES - VIRTUAL 2nd Annual Extractables & Leachables Conference 2020:

3P Biopharmaceuticals, ES - Abbott Healthcare Products B.V., NL - Abbvie Deutschland GmbH & Co. KG, DE - Accord-UK Ltd, UK - Advent Consulting Canada, CA - ALK, DK - Alkermes Pharma Ireland Limited, IE - Alphamed Formulations PVT LTD, IN - Apotex Research Pvt Ltd., IN - Aspen Holdings, ZA - Aspen Pharmacare, ZA - B.Braun medical SA, CH - Bavarian Nordic, DK - Becton Dickinson, CN - Becton Dickinson, FR - Biogen, USA - Boston Analytical, USA - Claudia Cusa, d.i., IT - CSL Behring AG, CH - Datwyler Pharma Packaging International NV, BE - DuPont, USA - DuPont-Asahi Flash Spun Products, JP - EirGen Pharma, IE - Eli Lilly and Company, USA - EMS SA, CH - Eurofins Analytical Science Laboratories, Inc., JP - Fujifilm Diosynth Biotechnologies, UK - GSK, US - GSK Vaccines, BE - Hall Analytical, UK - Hemofarm AD, RS - HTL-Strefa S.A., PL - Intertek (Schweiz) AG, CH - Janssen, USA - Kora Healthcare, IE - LEO Pharma, IE - Maven E&L Ltd, UK - Medline Industries, USA - Merck KGaA, DE - MilliporeSigma a business of Merck KGaA, USA - Novartis, CH - Novartis Pharma Stein AG, CH - NOVAVAX CZ a.s., CZ - Orexo AB, SE - Orion Corporation - FI, Philips, NL - Polifarma İlaç San. ve Tic. A.Ş., TR - PPD, IE - Rentschler Biopharma SE, DE - Safetree Consulting e.U., AT - Sandoz Manufacturing Inc., CA - Sanofi, FR - Sanofi, DE - Sanofi Pasteur, CA - Sartorius Stedim Biotech GmbH, DE - SCHOTT AG, DE - SCIEX, UK - Selvita S.A., PL - Septodont, FR - SGS, CN-TW - SGS Institut Fresenius GmbH, DE - Solvias AG, CH - Sthree, BE - Swedish Biomimetics 3000 Ltd, UK - Takeda Pharmaceuticals, USA - Vet-Agro Sp. z o.o., PL - West Pharmaceutical Services, USA - Wockhardt Ltd, IN - and others.

Agenda: https://qepler.com/agendas/agenda-2nd-extractables-and-leachables-20.pdf

POSITIONS

- C-Level, Presidents, Chairs, Members of the Board & VPs
- Vice presidents, Directors, & Heads
- Leaders & Managers
- Principals, Engineers, Analysts & Scientists
- Instructors & Trainers & Teachers
- Advisors, Coordinators, Auditors & Consultants
- Other Professionals, Experts & Specialists

DIVISIONS

- Aerosol Science
- Asthma
- Combination Products
- Connective Health
- COPD
- Cystic Fibrosis
- Device Development & Engineering
- Drug Development & Delivery
- Dry Powder Inhalers
- E-Health
- Formulation Development
- Formulation Development
- Generics
- Inhalation Delivery
- Inhalation Product Development
- Inhalation Products
- Inhaled Dosage Forms
- Medical Devices
- Metered Dose Inhalers
- Nasal Delivery
- New Materials
- Particle Characterisation
- Process Development
- Pulmonary Delivery
- Pulmonary Diseases
- R&D
- Regulatory Affairs
- Respiratory Delivery
- Respiratory Drug Delivery & Development
- Respiratory Supply Chain
- Respiratory Therapeutics
- Respiratory Pharmacology
- Scientific Research
- Marketing & Business Development
- Other

INDUSTRIES

- Pharmaceutical
- Biotechnology
- Chemical
- Medical Devices
- Plastics
- CMOs/CDMOs
- CROs
- NOPs
- Regulatory Agencies
- Training providers
- Other



INHALED DRUG DELIVERY

qepler

INHALED
DRUG DELIVERY
VIRTUAL SUMMIT
2021

August 5 | 1st DAY

Central European Summer Time (CEST, Prague, UTC/GMT +2 hours)

12:00 - 12:20 — **Registration**

12:20 - 12:30 — **Opening Address from the Chairman**

12:30 - 13:00

Understanding of regulations and requirements for OINDPs.

Direct link to HOPIN session: https://app.hopin.com/events/2nd-inhaled-drug-delivery-conference-2021/sessions/2cf6e546-f7cc-4251-9993-6cf091bd8ec7

- Overview of E&L for OINDPs
- What are Extractables and leachables
- Why most important for OINDPs
- Brief over view of regulations
- Case studies

Dr. Andrew Feilden, CSci CChem FRSC | European E&L strategic Director | **Hall Analytical, UK**

13:00 - 13:10 — **Q & A**

13:10 - 13:40

Aerodynamics and Air Flow Resistance of DPIs.

Direct link to HOPIN session: https://app.hopin.com/events/2nd-inhaled-drug-delivery-conference-2021/sessions/6e3eee08-d568-4e43-98a3-4a8ec24dabc8

- Introduction – The relevance of the air flow resistance
- The air flow inside of a DPI – An engineer's perspective
- Interaction with formulation – A completely different story
- Basic approach using a bypass – visualisation and modelling
- Summary

Dr. Herbert Watchel | Senior Principal Scientist | **Boehringer Ingelheim Pharma GmbH & Co. KG, DE**

13:40 - 13:50 — **Q & A**

13:50 - 14:00 — **Break**

14:00 - 14:30

Using the inhalation route to delivery drugs to the systemic circulation.

Direct link to HOPIN session: https://app.hopin.com/events/2nd-inhaled-drug-delivery-conference-2021/sessions/9d642ace-420a-43ab-bc20-3e2c1c506133

- Advantages and limitation of the pulmonary route to the systemic circulation
- Requirements for distal lung aerosol delivery
- Medicines for systemic inhalation therapy on the market and in the development pipeline
- Critical assessment of factors governing the success (or failure) of systemically inhaled products

Dr. Carsten Ehrhardt | Professor in Pharmaceutics and Biopharmaceutics | **Trinity College Dublin, IE**

14:30 - 14:40 — **Q & A**

14:40 - 15:10

Lung on chip applications in respiratory health.

Direct link to HOPIN session: https://app.hopin.com/events/2nd-inhaled-drug-delivery-conference-2021/sessions/4d3aadb8-a2a5-4d34-b9aa-bd846f4ddaed

Nina Hobi | CEO & Scientific Director | **AlveoliX AG, CH**

15:10 - 15:20 — **Q & A**



INHALED DRUG DELIVERY

qepler

INHALED
DRUG DELIVERY
VIRTUAL SUMMIT
2021

August 5 | 1st DAY

Central European Summer Time (CEST, Prague, UTC/GMT +2 hours)

15:20 - 16:05

Translating Inhaled and Nasal Technologies for the Delivery of Biologics.

SPONSOR

Direct link to HOPIN session: https://app.hopin.com/events/2nd-inhaled-drug-delivery-conference-2021/sessions/ca077f2e-3834-4f98-961c-28ae9ec77eb3

Inhaled and nasal delivery platforms have specific applications outside of their traditional uses for asthma/chronic obstructive pulmonary disease (COPD) and seasonal rhinitis/sinusitis: They can offer real advantages for the delivery of therapeutic biologics.

- Overview of currently available technologies and successfully marketed products.
- Review of the development challenges that might be encountered — and the solutions that are available — when formulating these delivery routes.
- A focus on analytical approaches for impurity identification and quantification.
- Key considerations when rapidly repurposing existing products for inhaled delivery.

Mark Parry | Technical Director | **Intertek Pharmaceutical Services, UK**

intertek
Total Quality. Assured.

16:05 - 16:15 — Q & A

16:15 - 16:25 — Break

16:25 - 16:55

Inhalation of therapeutics to fight respiratory tract infections.

Direct link to HOPIN session: https://app.hopin.com/events/2nd-inhaled-drug-delivery-conference-2021/sessions/c5a836cb-09a4-411f-8c22-eb114ad432fa

- Inhalation addresses drugs topically as an aerosol through the nose and/or mouth to its site of action in the respiratory tract. Actually, inhalation is the gold standard for the delivery of drugs with topical action to treat asthma, chronic obstructive respiratory disease (COPD) or cystic fibrosis (CF).
- Inhalation provides a better therapeutic index for some drugs, often requires reduced dose as compared to other routes and is non-invasive, improving patient compliance and comfort.
- Presently, most (topical) inhaled drugs are small molecules from different classes. Despite the obvious theoretical advantages of topical administration for therapeutics antibody (Ab) by inhalation, few of these benefits have yet materialized in the clinics.
- This paucity highlights the complexity of developing inhaled antibodies and points out the persisting hurdles to overcome. A detailed understanding of the biology and pharmacology of inhaled Ab is required to ensure the successful transition from pre-clinical to clinical assessment.

Thomas Sécher | Scientist | **INSERM, FR**

Inserm
La science pour la santé
From science to health

16:55 - 17:05 — Q & A

17:05 - 17:35

Transnasal Pulmonary Drug Delivery in Acute and Critical Care – Practice to Promise.

Direct link to HOPIN session: https://app.hopin.com/events/2nd-inhaled-drug-delivery-conference-2021/sessions/8c43d6f6-04cf-4101-af93-7f1b4255056b

- Administration of medical aerosols to the lung of our sickest patients has multiple challenges in the critical care environment including the need to not interrupt oxygen and ventilatory support.
- Aerosol delivery via High Flow Nasal Oxygen is used by >70% of intensivists worldwide for a variety of applications, with expanding knowledge of best practices of optimal delivery efficiency achieving double digit delivery efficiency in both preterm infants and adults.
- Knowable and controlable, transnasal pulmonary aerosol delivery has the promise of efficient and consistent administration of a wide range of formulations supporting development and approval of inhaled medications for management of the critically ill.

James B Fink, PhD, RRT, FAARC, FCCP | Chief Scientific Officer | **Aerogen Pharma Corp., USA**

Aerogen Pharma
Inspiring drugs for critical care

17:35 - 17:45 — Q & A

17:45 - 18:45 — Networking Hour



INHALED DRUG DELIVERY

qepler

INHALED
DRUG DELIVERY
VIRTUAL SUMMIT
2021

August 6 | 2nd DAY

Central European Summer Time (CEST, Prague, UTC/GMT +2 hours)

12:00 - 12:20 — **Registration**

12:20 - 12:30 — **Opening Address from the Chairman**

12:30 - 13:00

The climate is changing for metered dose inhalers.

Direct link to HOPIN session: https://app.hopin.com/events/2nd-inhaled-drug-delivery-conference-2021/sessions/6eda48e1-6985-4282-bcdb-f1c83801d36e

- Increases in global temperature are already having a significant impact on our climate. The hydrofluorocarbon (HFC) propellants used today in pressurized metered-dose inhalers (pMDIs) have global warming potential (GWP) many times that of carbon dioxide. This has prompted calls to switch patients to dry powder inhalers (DPIs)
- Dry powder inhalers are often more expensive than the equivalent pMDI. A wholesale switch of reliever medications would lead to significant increases in the cost of these life-saving medications
- At the same time, it is projected that there may be a 5-fold increase in the cost of pharmaceutical grade propellants in the next few years. This may lead to a price increase in reliever medication
- At least two companies are now working to develop pMDIs using propellants which are potentially cheaper in the long-term and have much lower GWP

Dr. John N Pritchard | Independent Business Owner | **Inspiring Strategies, UK**

13:00 - 13:10 — **Q & A**

13:10 - 13:40

Practical challenges with developing inhalation drugs during pre-clinical testing.

Direct link to HOPIN session: https://app.hopin.com/events/2nd-inhaled-drug-delivery-conference-2021/sessions/0f184786-aef5-4939-a48b-a65538dc25d6

- Extrapolating from clinical to pre-clinical and regulatory expectations
- Study designs – what is different for inhalation studies – histo, animal numbers or not, dose calculation
- NCEs vs biologics – differences or not
- Aerosol generation, exposure systems, aerosol sampling, additional DFA/FIA support
- Animal welfare considerations – TK blood volumes, BAL collection, limitations of dosing wrt time, dosing large animals – animal compliance

Dr. Simon Moore, BSc(Hons) PhD MRSC | Global Lead of Inhalation Sciences and Engineering
Covance Laboratories, UK

COVANCE SOLUTIONS MADE REAL

13:40 - 13:50 — **Q & A**

13:50 - 14:00 — **Break**

14:00 - 14:30

From perception to use - the patient DPI product interface.

Direct link to HOPIN session: https://app.hopin.com/events/2nd-inhaled-drug-delivery-conference-2021/sessions/3a0a9a8a-e2c6-4222-b84a-e3ec2eefdafe

- Patient characteristics and therapeutic complexity
- DPI product administration from a patient perspective
- The role of learning, intuition and standardization
- TDPI product design to improve therapeutic outcomes

Univ.-Prof. Dr. Sven Stegemann | Professor for Patient Centric Drug Development & Manufacturing
Graz University of Technology, AT

TU Graz

14:30 - 14:40 — **Q & A**

14:40 - 15:10

Are sustainability, reusability and carbon neutrality major trends for devices in the future? A case study of Respimat® re-usable.

Direct link to HOPIN session: https://app.hopin.com/events/2nd-inhaled-drug-delivery-conference-2021/sessions/521829cc-025f-42bf-ad91-c221e5919789

- Historic and upcoming political initiatives
- Carbon footprint and neutrality
- Respimat® re-usable - technology and performance
- Sustainability goes beyond design

Dr. Felix Weiland | Head of Product & Process Technology | **Boehringer Ingelheim microParts GmbH, DE**

Boehringer Ingelheim microParts

15:10 - 15:20 — **Q & A**



INHALED DRUG DELIVERY

qepler

INHALED
DRUG DELIVERY
VIRTUAL SUMMIT
2021

August 6 | 2nd DAY

Central European Summer Time (CEST, Prague, UTC/GMT +2 hours)

15:20 - 15:30 — **Break**

15:30 - 16:10 — **SPONSOR**

The impact of filling technology selection for dry powder formulations on device performance, process consistency and commercial scale-up.

Direct link to HOPIN session: https://app.hopin.com/events/2nd-inhaled-drug-delivery-conference-2021/sessions/2ecd49b6-f8c2-40ce-882b-7c81b4d67132

- Consistent high efficiency aerosoliation performance is a critical quality attribute for all dry powder inhalers. There is a strong dependant relationship between the powder formulation, filling technology, device design and the device performance.
- The desire to deliver a wider range of molecular types of drug has promoted a large increase in the use of engineered particle technologies e.g. spray drying for DPIs which require careful consideration of process conditions.
- Highlight the impact of filling technology on device performance, process efficiency and manufacturing throughput. Could selection of the right filling technologies enable increased formulation and device design spaces.
- Assess the potential issues due to filling technology with process scale-up to achieve continuity of performance as you move from bench, through clinic to commercial; minimising risk in the development process.
- Affirm the importance of early stage filling trials on formulation selection and device design.

Tom French | Device Industrialisation Engineer | **3P innovation, UK**

16:10 - 16:20 — **Q & A**

16:20 - 16:50

Postmarket Safety reporting for Combination products in the US

Direct link to HOPIN session: https://app.hopin.com/events/2nd-inhaled-drug-delivery-conference-2021/sessions/8f02555e-1bbc-442f-beed-c223c730d3b8

- What are the regulatory requirements
- Discussion of key challenges
- Walk through a reportable event case scenario

Khaudeja Bano, MD | Executive Medical Director, Combination Product Safety Head Global Patient Safety & Pediatrics | **Amgen, USA**

16:50 - 17:00 — **Q & A**

17:00 - 17:30

ICOpre - Development of a generic DPI platform for a global market.

Direct link to HOPIN session: https://app.hopin.com/events/2nd-inhaled-drug-delivery-conference-2021/sessions/fde73368-8fe6-47ce-863d-2399701faa43

Generic versions of marketed dry powder inhaler (DPI) drug products represent an attractive market opportunity. In the coming years, GSK's Ellipta platform is the largest opportunity with several drug substance patents expiring. However, development of generic DPI drug products is a complicated process with many challenges. Complex drug-device interactions represent a major hurdle to achieve therapeutic equivalence. The very intricate patent landscape in combination with the requirement of similar user-handling and flow resistance limits the design options. The need for cost-efficient development and low manufacturing costs adds additional complexity. There is a great need to replace injections with safe and low cost inhaled drug delivery. Iconovo's unit-dose inhaler ICOone is currently used in two ongoing projects on inhaled oxytocin and inhaled covid-19 vaccine.

- Overview of market and patent situation.
- Regulatory requirements on generic inhalation products.
- Initial choice – copy original or develop new technology.
- Concurrent development of device and formulation.
- ICOone – inhalation instead of injection.

Dr. Orest Lastow | Chief Technology Officer & Founder | **Iconovo AB, SE**

17:30 - 17:40 — **Q & A**

17:40 - 18:40 — **Networking Hour**

18:40 - 18:50 — **Closing remarks and end of conference**

SPEAKER'S BIOGRAPHIES

Dr. Andrew Feilden
European E&L strategic Director
Hall Analytical, UK

Dr. Andrew Feilden is the European E&L strategic Director at Hall Analytical. Prior to that he was the Chemistry Operations Director, for 6 years, where he lead the chemistry group at the Shawbury site in the UK. The Shawbury site carries out extractable and leachable testing, GPC analysis and food contact testing. He has delivered numerous international podium presentations on Extractables and leachables.
Andrew has been with Smithers for over 7 years, prior to that he worked for AstraZeneca, specialising in Extractables and Leachables. He has a degree and D Phil from the university of York, is a Fellow of the Royal Society of Chemistry and is a Scientific advisor to IPAC-RS.

Dr. Felix Weiland
Head of Product & Process Technology
Boehringer Ingelheim microParts GmbH, DE

Felix is a pharmacist by training with a PhD in pharmacology. In 2006, he joined Boehringer Ingelheim as a trainee, focusing on launch and transfer activities of inhalative products. He then took over different roles at BI microParts in Dortmund at the development site of inhalation devices as development QA manager, senior project manager, and lab head of device development. In 2010, he joined the Ger-resheimer Group at Bünde as a QC head and later as quality director. Buende is a large-scale manufacturing site of sterile primary packaging components, i.e.RTF®- syringes and insulin cartridges. In 2015, he returned to Boehringer Ingelheim to implement systems for systematic life cycle management of the Respimat® Plat¬form Technology, including ownership of the design history files. Currently he is the director of product- & process-technology including responsibilities for project management, design verification laboratories, clinical trial supply, and design & process technology of devices.

Dr. Herbert Watchel
Senior Principal Scientist
Boehringer Ingelheim Pharma **GmbH & Co. KG, DE**

Dr. Herbert Wachtel is a Senior Principal Scientist at Boehringer Ingelheim, Germany. Boehringer Ingelheim is a global, research-driven pharmaceutical company embracing many cultures and diverse societies. Within its business unit Prescription Medicines, Respiratory is one of the major areas. Herbert has joined the company in 1998 and since then he has been involved in basics of inhalation therapy, e.g. formulation development, novel methods for particle sizing, design of aerodynamic components in inhalers and aerosol therapy in children. In his spare time Herbert serves as a lecturer on the subject of Pharmaceutical Technology at the Johannes Gutenberg-University in Mainz.
Herbert has studied Physics at the University of Stuttgart where he investigated conducting molecular solid films and surfaces before switching to the field of aerosolized drug delivery. Apart from CAD tools, Herbert regularly applies Computational Fluid Dynamics (CFD) and he advances up-to-date 'in vivo-in vitro correlations' (IV-IVC) for the optimization of devices in the industrial setting.

Dr. Carsten Ehrhardt
Professor in Pharmaceutics and Biopharmaceutics
Trinity College Dublin, IE

Carsten is Professor in Pharmaceutics and Biopharmaceutics and Fellow at Trinity College Dublin. He also holds an Adjunct Professorship at the University of Southern California. His research is focused on lung drug disposition and pulmonary epithelial transport. Moreover, he is interested in molecular origins of airways disease. Carsten has edited 1 book and (co-) authored 98 peer-reviewed publications and over 250 abstracts. He is the recipient of honours and awards from German Pharmaceutical Society (DPhG), American Physiological Society and Galenus Foundation.
Carsten serves as Section Editor of European Journal of Pharmaceuticals Sciences and is a member of the Editorial Boards of American Journal of Physiology - Lung Cellular and Molecular Physiology, European Journal of Pharmaceutics and Biopharmaceutics, Journal of Aerosol Medicine and Pulmonary Drug Delivery, Journal of Pharmaceutical Sciences, Pharmaceutics, and Pharmaceutical Research.

Dr John N Pritchard
Independent Business Owner
Inspiring Strategies, UK

From January 2011 - September 2018, John was CTO for Philips Respironics Drug Delivery, with global accountability for the development of products for the treatment of respiratory diseases. He is now a private consultant specialising in strategic approaches to developing respiratory devices, drugs and digital health. At different stages in his career across 3 major pharmaceutical companies, he has been associated with the launch of 11 major products and at RDD in April 2018, John received the Charles Thiel award for outstanding research and discovery in respiratory drug delivery. John has published widely in the field, as well as having served as Board member on various scientific and industry bodies. He has sat on a number of Advisory Boards and is currently a member of the UN Committee that makes recommendations on the essential uses of propellants.

Univ.-Prof. Dr. Sven Stegemann
Professor for Patient Centric Drug Development & Manufacturing
Graz University of Technology, AT

Sven Stegemann is professor of patient centric drug design and manufacturing at the Graz University of Technology, Austria. Over the course of his 21-year career he has worked as an advisor to major pharmaceutical companies on ways to improve the design, development and manufacture of pharmaceutical products so they better address the individual needs of patients. In his academic role, he focuses his research on the rational development of patient centric drug products and their associated manufacturing technologies, as well as education and training of students and young scientists. He is the founder and chair of the AAPS Focus Group on Patient-Centric Drug Development, Product Design, and Manufacturing as well as the founder and President of the Geriatric Medicine Society e.V.. He recently started the industrial-academic collaboration partnership Patient Centric Medicine (PaCeMe) to suitable and meaningful guidance for patient centric drug product design. He is the editor of the book "Developing Drug Products in an Aging Society - From Concept to Prescribing", a multidisciplinary approach towards patient centric drug development for the older and multimorbid patient populations.

Thomas Sécher
Scientist
INSERM, FR

Thomas is a research scientist in the field of mucosal immunology and therapeutics. He is particularly concerned about infectious diseases and the way we can prevent them. Quickly realized the importance of the host-pathogen-environment triad in determining the outcome of infectious events and he was fascinated by the host-pathogen dualism and how their interactions dictate pathogenesis and subsequently modulate the efficacy of therapeutics. Studying this in more details has always been the driving force of my research.
Thomas owned a PhD in immunology/infectiology and have more than 10 years of experience in mucosal immunology and experimental disease models. After pursuing research projects at the CNRS (UMR 6218, Orléans, France) and INSERM (UMR1043, Toulouse, France), he joined the Research Center for Respiratory Diseases in Tours in 2016. His research interests are mainly focused on proof-of-concept for aerosol delivery of biotherapeutics and mainly therapeutic antibodies to treat respiratory tract infections.
Thomas (co-)authored more than 40 peer-reviewed publications, 1 patent and has given more than 20 oral presentations. He was a member of the scientific committee for the 7th (2019) and 9th (2021) AIS congress and actively serves as reviewer for Frontiers in Immunology, Frontiers in Microbiology, Gut and Plos One.

qepler

REGISTRATION FORM

This registration form is editable.
When you have completed the form - please save and email it to register@qepler.com

SUMMIT NAME: VIRTUAL - 2nd Annual Inhaled Drug Delivery Summit 2021

REGISTRATION DATE:

PACKAGE NAME	Standard price	
Individual ticket - 1st Day (5th August 2021) - (*includes 1st Day's post-event conference materials distribution)	€195	☐
Individual ticket - 2nd Day (6th August 2021) - (*includes 2nd Day's post-event conference materials distribution)	€195	☐
Individual ticket - 2 Days - (*includes complete post-event conference materials distribution)	€295	☐
Group ticket - 2 Days (*2-3 delegates) - (*includes complete post-event conference materials distribution)	€215	☐
Group ticket - 2 Days (*4+ delegates) - (*includes complete post-event conference materials distribution)	€145	☐
Documentation package - (*if you have no plans to join the live conference)	€395	☐
Promotional materials distribution	€445	☐
SPEAKER SPONSOR - €995 ☐	PARTNER SPONSOR - €1295 ☐	GOLD SPONSOR - €1695 ☐

CONFERENCE MATERIALS:
All participation tickets, already contains complete conference materials distribution package, including - slides, list of participants, stream and video recording. You don't need to order an additional «Documentation Packages».
Documentation package will be sent to the attendees within 72 hours after the event. The presentation content is subject to speaker's companies approval for distribution.

ATTENDEE DETAILS	1ST ATTENDEE	2ND ATTENDEE	3RD ATTENDEE	4TH ATTENDEE	5TH ATTENDEE	6TH ATTENDEE
Title:						
Name:						
Surname:						
Company:						
Country:						
Job Title:						
Direct phone:						
Email:						
Special Requirenments: (If you have any special dietary requirements or other needs that would enhance your enjoyment of this summit, please specify)						

INVOICE DETAILS:

Title: _____ Name: _____ Surname: _____

Job Title: _____

Direct Phone: _____ Mobile: _____ Email: _____

Company: _____ Country: _____ City: _____ EU VAT #: _____

Address: _____ Postcode: _____

Payment Method: Bank Transfer ☐ Credit Card ☐ Pay Pall ☐

TERMS & CONDITIONS:

REGISTRATION & PAYMENT
Upon receiving the signed registration form, we will process your application. The registration confirmation and the invoice will be sent to you within one (1) working day with the relevant payment instructions and terms. The registration fee includes access to all sessions and conference materials. Payment is due 14 working days from the invoice date. Payment should be made by Credit Card, Pay Pall or by Bank Transfer. The delegate is responsible for any bank charges/fees associated with the payment.

CANCELLATION & SUBSTITUTION POLICY
You may substitute a delegate at any time and at no extra cost. Cancellations must be in a written notice. Cancellations made 30 days or more before the event start date will be refunded less than 50% of the registration fee. Cancellations made less than 30 days before the event start date will receive no refund. If you cannot attend an event due to illness or other unforeseen circumstances, you may transfer your delegate pass to another upcoming event within one year from original event start date.

EVENT CHANGES & CANCELLATIONS
While all effort will be made to adhere to the advertised package, Qepler s.r.o. reserves the right to change event dates, sites or location, omit event features, or merge the event with another event as it deems necessary without penalty. In such situations no refunds, part refunds or alternative offers will be made. In the event that Qepler s.r.o. permanently cancels the event for any reason, and provided that the event is not postponed to a later date nor is merged with another event, you will receive a credit note or refund for 100% of the conference fee paid. Please note, Qepler s.r.o. will not be held liable for any accommodation or associated travel costs should the event be canceled or rescheduled.

DATA PROTECTION
The personal information provided by you will be held in the Qepler database. It may be used to infrom you about other Qepler products and services. Unless you click here ☐, your details may be made available to third parties for marketing purposes.
For data update please write to databasemanager@qepler.com.

Signature:
«I agree to be bound by Terms and Conditions of registration»

SEND

PARTICIPATION PACKAGES

qepler

ONLINE PACKAGES:

If you are unable to attend, you may purchase these packages

PACKAGE NAME	PRICE
DOCUMENTATION (*if you have no plans to join the live conference) Post-event presentations with video records, list of participants and other materials. The presentation content is subject to speaker's companies approval for distribution.	€395
PROMOTIONAL MATERIALS DISTRIBUTION Distribution of your company's promotional materials to all attendees	€445

SPONSORSHIP PACKAGES:

BENEFITS	SPEAKER €995	PARTNER €1295	GOLD €1695
Number of passes included	1	2	3
Registration fee for additional company representatives	€195	€145	€95
Link to Landing Page/Video Presentation trough the live event translation.		•	•
Link to Virtual Exhibition Page trough the live event translation.			•
Opening keynote presentation			15 min
Speaking slot	20 min	30 min	30 min
Workshop slot			40 min
Recognition in chairman's opening address		•	•
Opening & closing speech			•
Chairman of Day 1			•
Chairman of Day 2		•	
Logo and URL on summit website, agenda and pre/post-summit communication activities	•	•	•
Recognition on Qepler social media channels (LinkedIn/Facebook/Twitter/Instagram)	•	•	•
Color advert placed on agenda		1/2 Page	1 Page
Online distribution of your company's promotional materials to all attendees		•	•

MARKETING CAMPAIGN

▸ Website ▸ Email Marketing ▸ Digital Advertising ▸ Social Marketing ▸ Press ▸ Direct Sales

PARTICIPATION FEE

Fees are inclusive of the complete summit materials, online post-event documentation/presentation package, list of participants, video records, and certificate of participation.

TRANSLATION

The event translation link will be announced online and sent to the delegates within a reasonable period before the summit start date.

POST-EVENT DOCUMENTATION

Presentations and other materials will be sent to the attendees within 72 hours after the event. The presentation content is subject to speaker's companies approval for distribution.

DISCOUNTS

Early booking discounts are not valid in conjunction with any other offers.

www.qepler.com
+420 608 030 490
register@qepler.com

WAYS TO REGISTER

EVENTS CALENDAR 2021

Please **choose** the **Summit / Summits** and **send** us suggested **Session Title** via email or webpage.
We will appreciate if you **share** our **calendar with** your **colleagues**!

qepler

CLICK HERE TO REQUEST INFORMATION

PHARMA - MEDICAL DEVICES - CHEMISTRY

DRUG DELIVERY - FORMULATION - R&D - DEVICES - COMBINATION PRODUCTS - PFS - LYOPHILIZATION - E & L - IMPURITIES - HPAPI - INHALATION - ASEPTIC PROCESSING - MDR - CMC - QRM - PFS - DDC - EM

2nd Genotoxic Impurities in Pharmaceuticals Summit ..... July 15-16, 2021
- VIRTUAL CONFERENCE

GTI strategies & new methodologies: analysis, in silico & regulations. Challenges & opportunities.
https://qepler.com/pdf/v2gti21.pdf
REGISTRATION IS OPEN
AGENDA WEB

3rd Annual Pharmaceutical Lyophilization Summit ..... July 29-30, 2021
- VIRTUAL CONFERENCE

Discuss best practices in tech & regulatory updates, process, formulation, testing, monitoring, new products development.
https://qepler.com/pdf/v3lyo21.pdf
REGISTRATION IS OPEN
AGENDA WEB

2nd Annual Inhaled Drug Delivery Summit ..... August 5-6, 2021
- VIRTUAL CONFERENCE

Assess and harness novel approaches to the development of inhaled drug products for enhanced patient care.
https://qepler.com/pdf/v2idd21.pdf
REGISTRATION IS OPEN
AGENDA WEB

3rd Annual Highly Potent APIs Summit ..... October 7-8, 2021
- VIRTUAL CONFERENCE

Assess and reduce manufacturing and handling challenges for highly potent active pharmaceutical ingredients.
https://qepler.com/pdf/v3hpapi21.pdf
REGISTRATION IS OPEN
AGENDA WEB

3rd Annual Extractables & Leachables Summit ..... October 20-21, 2021
- VIRTUAL CONFERENCE

Get the latest updates in regulation, analytical testing, risk & safety assessment, biocompatibility.
https://qepler.com/pdf/v3el21.pdf
REGISTRATION IS OPEN
AGENDA WEB

3rd Annual Drug/Device Combination Products Summit ..... December 2-3, 2021
- VIRTUAL CONFERENCE

Get up to date with the regulatory and quality compliance strategies for combination product development.
https://qepler.com/pdf/v3ddcp21.pdf
REGISTRATION IS OPEN
AGENDA WEB

CONTACTS

Please send your session title and summit name to:

Denis Polikarpov
Executive Director
Tel: +420 608 030 490
Email: denis.polikarpov@qepler.com

Evgenia Makar
CEO
Tel: +420 770 699 211
Email: evgenia.makar@qepler.com